Hospital Alvaro Cunqueiro
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Hospital Alvaro Cunqueiro, investigators are evaluating whether early use of candesartan can prevent a meaningful decline in heart function for genetic carriers of dilated cardiomyopathy, aiming to preserve left ventricular performance before symptoms appear.
- Early pharmacologic intervention in at‑risk patients
- Monitoring left ventricular ejection fraction as a primary endpoint
- Assessing ventricular remodeling through imaging biomarkers
The cardiology unit is conducting three trials with a team of 48 investigators, focusing on innovative prevention strategies for heart muscle disease.
Congenital, Hereditary, and Neonatal Diseases
The department is dedicated to studying hereditary forms of dilated cardiomyopathy, specifically targeting individuals who carry disease‑causing variants but have not yet manifested clinical signs, to evaluate the protective effect of early therapy.
- Genetic screening and identification of at‑risk family members
- Placebo‑controlled assessment of disease progression
- Long‑term safety monitoring of ARB treatment in asymptomatic carriers
With 48 researchers involved, the site’s three clinical trials aim to translate genetic insights into preventive care for inherited heart conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 18 therapeutic areas and 15 of 226 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 204 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 45 by active trials.
- 1AstraZeneca AB4active
lock +44 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB7trials
lock +21 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Alvaro Cunqueiro
lock Showing 1 of 112 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) | Amgen Inc. | Phase III | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 226 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 8 | Unknown | 2023-03-28 | 2026-03-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.